AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Average Price Target of $37.50

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have received an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $37.50.

AGMB has been the topic of a number of recent analyst reports. Wall Street Zen cut AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating on the stock. Finally, Piper Sandler began coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target on the stock.

AgomAb Therapeutics Stock Performance

Shares of AgomAb Therapeutics stock opened at $8.56 on Wednesday. AgomAb Therapeutics has a 12-month low of $8.00 and a 12-month high of $17.82. The firm’s 50-day moving average price is $12.97 and its two-hundred day moving average price is $12.07.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Equities research analysts anticipate that AgomAb Therapeutics will post -1.76 EPS for the current year.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.